Sanofi Expands Canadian Access to Dupixent Treatment

A new agreement will broaden public payer coverage for patients suffering from four additional chronic inflammatory conditions.

Updated on Oct. 15, 2026 in Asthma

Bold flat-color editorial illustration showing a grid of abstract glass vials, symbolizing expanded access to medical treatments in Canada. — Sanofi and the pan-Canadian Pharmaceutical Alliance have reached an agreement to expand public payer coverage for Dupixent across four additional chronic conditions. AI Illustration. Upload story photo >

Live Poll

Should federal drug programs prioritize faster patient access to expensive new biologic therapies?

Sanofi and the pan-Canadian Pharmaceutical Alliance have signed a Letter of Intent to increase patient access to Dupixent. The deal covers usage for pediatric atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyposis, and COPD.

Why it matters

This agreement aims to bridge critical treatment gaps for Canadians living with type 2 inflammatory diseases. It facilitates easier access to biologic therapy for thousands of patients currently navigating chronic, debilitating conditions.

Dupixent inhibits the signaling of interleukin-4 and interleukin-13 pathways to manage inflammatory conditions. These new indications will support care for a population where COPD affects approximately 9% of Canadians aged 35 and older.

The players

Sanofi

Sanofi is a global healthcare company that employs over 2,000 people in Canada and focuses on innovative solutions for complex diseases.

pan-Canadian Pharmaceutical Alliance

The pan-Canadian Pharmaceutical Alliance conducts joint provincial, territorial, and federal negotiations to achieve greater value for public drug programs.

The details

Sanofi will collaborate with provinces, territories, and federal drug programs to implement the expanded coverage. The drug is currently used by 45,000 Canadians, and this expansion addresses needs for conditions like atopic dermatitis, which affects 15% of children and 4% of adults nationwide.

October 15, 2026: Sanofi and the pCPA signed the Letter of Intent.
2028: Sanofi expects to complete $2 billion in infrastructure investments.

Health Landscape

This agreement follows the standards set by the pan-Canadian Pharmaceutical Alliance negotiation framework to standardize drug access across provinces. It marks a significant shift toward integrating biologic therapies into public formularies for complex chronic diseases.

Patients who previously struggled to access Dupixent through public plans may soon see new coverage options for their specific inflammatory conditions. This change could significantly reduce out-of-pocket costs and improve access to long-term care for thousands of Canadians.

The takeaway

Patients should consult with their healthcare providers to determine if these new covered indications align with their current treatment plans. This shift highlights a broader move toward increasing public access to advanced biologic therapies for chronic health conditions.